JP2010505741A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505741A5
JP2010505741A5 JP2009509880A JP2009509880A JP2010505741A5 JP 2010505741 A5 JP2010505741 A5 JP 2010505741A5 JP 2009509880 A JP2009509880 A JP 2009509880A JP 2009509880 A JP2009509880 A JP 2009509880A JP 2010505741 A5 JP2010505741 A5 JP 2010505741A5
Authority
JP
Japan
Prior art keywords
oligomer
cationic
bond
bonds
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009509880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505741A (ja
Filing date
Publication date
Priority claimed from US11/432,031 external-priority patent/US8084433B2/en
Priority claimed from US11/432,155 external-priority patent/US20070037763A1/en
Priority claimed from US11/431,968 external-priority patent/US8785407B2/en
Priority claimed from US11/432,216 external-priority patent/US7625873B2/en
Priority claimed from US11/433,033 external-priority patent/US8415313B2/en
Priority claimed from US11/433,213 external-priority patent/US20070004661A1/en
Priority claimed from US11/433,214 external-priority patent/US8067569B2/en
Priority claimed from US11/433,840 external-priority patent/US7507196B2/en
Priority claimed from US11/433,724 external-priority patent/US7888012B2/en
Priority claimed from US11/433,257 external-priority patent/US20070037764A1/en
Priority claimed from US11/518,058 external-priority patent/US8329668B2/en
Priority claimed from US11/517,757 external-priority patent/US8524676B2/en
Priority claimed from US11/595,161 external-priority patent/US20070111962A1/en
Priority claimed from US11/715,572 external-priority patent/US7582615B2/en
Application filed filed Critical
Priority claimed from PCT/US2007/011435 external-priority patent/WO2008036127A2/en
Publication of JP2010505741A publication Critical patent/JP2010505741A/ja
Publication of JP2010505741A5 publication Critical patent/JP2010505741A5/ja
Pending legal-status Critical Current

Links

JP2009509880A 2006-05-10 2007-05-10 カチオン性のサブユニット間結合を有するオリゴヌクレオチドアナログ Pending JP2010505741A (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US11/432,216 US7625873B2 (en) 2004-07-02 2006-05-10 Antisense antibacterial method and compound
US11/432,031 US8084433B2 (en) 2004-09-16 2006-05-10 Antisense antiviral compound and method for treating ssRNA viral infection
US11/431,968 US8785407B2 (en) 2006-05-10 2006-05-10 Antisense antiviral agent and method for treating ssRNA viral infection
US11/432,155 US20070037763A1 (en) 2003-12-24 2006-05-10 Oligonucleotide compound and method for treating nidovirus infections
US80007606P 2006-05-11 2006-05-11
US79997606P 2006-05-11 2006-05-11
US80012006P 2006-05-11 2006-05-11
US80014506P 2006-05-11 2006-05-11
US11/433,840 US7507196B2 (en) 2004-11-01 2006-05-11 Antisense antiviral compounds and methods for treating a filovirus infection
US11/433,033 US8415313B2 (en) 2004-01-23 2006-05-11 Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US11/433,257 US20070037764A1 (en) 2003-10-23 2006-05-11 Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US11/433,213 US20070004661A1 (en) 2004-10-26 2006-05-11 Antisense antiviral compound and method for treating influenza viral infection
US11/433,724 US7888012B2 (en) 2005-02-09 2006-05-11 Antisense composition and method for treating muscle atrophy
US11/433,214 US8067569B2 (en) 2000-05-04 2006-05-11 Splice-region antisense composition and method
US11/517,757 US8524676B2 (en) 2005-09-08 2006-09-08 Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
US11/518,058 US8329668B2 (en) 2005-09-08 2006-09-08 Antisense antiviral compound and method for treating picornavirus infection
US11/595,161 US20070111962A1 (en) 2005-11-08 2006-11-08 Immunosuppression compound and treatment method
US11/715,572 US7582615B2 (en) 2006-03-07 2007-03-07 Antisense antiviral compound and method for treating arenavirus infection
PCT/US2007/011435 WO2008036127A2 (en) 2006-05-10 2007-05-10 Oligonucleotide analogs having cationic intersubunit linkages

Publications (2)

Publication Number Publication Date
JP2010505741A JP2010505741A (ja) 2010-02-25
JP2010505741A5 true JP2010505741A5 (enExample) 2010-07-01

Family

ID=40134113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009509880A Pending JP2010505741A (ja) 2006-05-10 2007-05-10 カチオン性のサブユニット間結合を有するオリゴヌクレオチドアナログ

Country Status (14)

Country Link
US (1) US7943762B2 (enExample)
EP (2) EP2024499B1 (enExample)
JP (1) JP2010505741A (enExample)
AU (1) AU2007297861A1 (enExample)
CA (1) CA2651881A1 (enExample)
CY (2) CY1120409T1 (enExample)
DK (2) DK2024499T3 (enExample)
ES (2) ES2657400T3 (enExample)
HU (2) HUE035799T2 (enExample)
LT (2) LT2735568T (enExample)
PL (1) PL2735568T3 (enExample)
PT (1) PT2735568T (enExample)
SI (2) SI2024499T1 (enExample)
WO (1) WO2008036127A2 (enExample)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
ES2351976T3 (es) 2003-04-29 2011-02-14 Avi Biopharma, Inc. Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células.
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
EP1713332A4 (en) * 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
SI2206781T1 (sl) 2004-06-28 2016-05-31 The University Of Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
WO2006085973A2 (en) 2004-07-02 2006-08-17 Avi Biopharma, Inc. Antisense antibacterial method and compound
US8129352B2 (en) * 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
ES2852549T3 (es) * 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007030691A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20070265215A1 (en) * 2006-05-11 2007-11-15 Iversen Patrick L Antisense restenosis composition and method
AU2015200600B2 (en) * 2007-06-29 2017-04-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2008271050B2 (en) * 2007-06-29 2014-11-06 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
WO2009014177A1 (ja) * 2007-07-25 2009-01-29 Ajinomoto Co., Inc. ジベンゾフルベン誘導体の淘汰方法
US8299206B2 (en) * 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
CA2884340C (en) * 2007-11-15 2017-07-25 Sarepta Therapeutics, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) * 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
CA2710013A1 (en) * 2007-12-28 2009-07-09 Avi Biopharma, Inc. Immunomodulatory agents and methods of use
EP2762567B1 (en) 2008-10-24 2016-07-13 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
US8592386B2 (en) * 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US9914745B2 (en) * 2009-08-14 2018-03-13 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
US8999675B2 (en) * 2009-08-31 2015-04-07 Gen-Probe Incorporated Dengue virus assay
SMT201800579T1 (it) 2009-11-12 2019-01-11 Univ Western Australia Molecole antisenso e metodi per trattare patologie
CA2779830C (en) 2009-11-13 2020-07-21 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
EP2542678B1 (en) 2010-03-04 2017-04-12 InteRNA Technologies B.V. A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
WO2011113015A2 (en) * 2010-03-12 2011-09-15 Avi Biopharma, Inc. Antisense modulation of nuclear hormone receptors
EP3023496B1 (en) * 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Compounds which modulate interleukins 17 and 23 signaling activity
AU2013202731B2 (en) * 2010-05-28 2016-04-21 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
JP2013530154A (ja) 2010-05-28 2013-07-25 サレプタ セラピューティクス， インコーポレイテッド 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
EP3369817A1 (en) 2010-07-06 2018-09-05 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
PL2623507T3 (pl) * 2010-09-30 2017-03-31 Nippon Shinyaku Co., Ltd. Pochodna kwasu morfolinonukleinowego
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
US8636875B2 (en) 2011-01-20 2014-01-28 Hercules Incorporated Enhanced dry strength and drainage performance by combining glyoxalated acrylamide-containing polymers with cationic aqueous dispersion polymers
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA2839593A1 (en) 2011-07-15 2013-01-24 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
BR112014011875B1 (pt) * 2011-11-18 2022-01-04 Sarepta Therapeutics, Inc Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
EP2785729B1 (en) * 2011-11-30 2020-11-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
AU2012345638C1 (en) * 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
PT2788487T (pt) 2011-12-08 2018-07-03 Sarepta Therapeutics Inc Análogos de oligonucleótido visando lmna humano
EP2794881B1 (en) 2011-12-22 2018-06-27 InteRNA Technologies B.V. Mirna for treating head and neck cancer
CA2868174A1 (en) 2012-03-20 2013-09-26 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
MX369519B (es) 2012-09-25 2019-11-11 Genzyme Corp Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica.
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
KR20150099804A (ko) 2012-12-20 2015-09-01 사렙타 쎄러퓨틱스 인코퍼레이티드 근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물
CN103060325B (zh) * 2013-01-14 2015-01-07 韩健宝 抗猪流行性腹泻病毒pedv的反义核酸及肽核酸pna
AU2014236140B2 (en) 2013-03-14 2019-10-03 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
KR20230074606A (ko) 2013-03-14 2023-05-30 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이영양증의 치료를 위한 엑손 스키핑 조성물
NZ732507A (en) 2013-03-15 2018-08-31 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
IL282239B2 (en) 2013-09-05 2023-10-01 Sarepta Therapeutics Inc Antisense-induced exon2 inclusion in acid alpha-glucosidase
ES2739850T3 (es) 2013-09-11 2020-02-04 Synthena Ag Acidos nucleicos y procedimientos para el tratamiento de la enfermedad de Pompe
US20170182189A1 (en) 2014-05-23 2017-06-29 Genzyme Corporation Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
EP3208277A4 (en) * 2014-10-14 2018-06-13 Ajinomoto Co., Inc. Morpholino oligonucleotide manufacturing method
MA41795A (fr) * 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2016196670A1 (en) 2015-06-01 2016-12-08 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type vii collagen
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
EP3340967B1 (en) 2015-08-24 2024-05-22 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
MA42695A (fr) * 2015-08-28 2018-07-04 Sarepta Therapeutics Inc Oligomères antisens modifiés pour l'inclusion d'exons dans l'atrophie musculaire spinale
WO2017059131A1 (en) 2015-09-30 2017-04-06 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
WO2017184529A1 (en) 2016-04-18 2017-10-26 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
NZ747685A (en) 2016-04-29 2023-05-26 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
CN109563114B (zh) * 2016-05-24 2022-08-12 萨勒普塔医疗公司 用于制备寡聚物的方法
CN109937042B (zh) * 2016-09-20 2023-06-27 科罗拉多州立大学董事会法人团体 使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体
KR102810425B1 (ko) 2016-12-19 2025-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
SG10202107429WA (en) 2017-01-06 2021-08-30 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
EP3593144A1 (en) 2017-03-10 2020-01-15 UCL Business Ltd Method relating to myostatin pathway inhibition
SG10201705285SA (en) * 2017-06-27 2019-01-30 Agency Science Tech & Res Antisense oligonucleotides
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
TWI812647B (zh) * 2017-09-25 2023-08-21 美商薩羅塔治療公司 經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程
CN111655268B (zh) 2017-10-04 2024-03-26 艾维迪提生物科学公司 核酸-多肽组合物及其用途
JP7356416B2 (ja) 2017-10-17 2023-10-04 サレプタ セラピューティクス， インコーポレイテッド 二環式ペプチドオリゴヌクレオチドコンジュゲート
TW202423453A (zh) * 2017-10-17 2024-06-16 美商薩羅塔治療公司 用於反義遞送之細胞穿透肽
EP3697910A4 (en) 2017-10-18 2021-07-14 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMER COMPOUNDS
EP3704250A1 (en) 2017-11-03 2020-09-09 InteRNA Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
CN118638787A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
AU2019218557A1 (en) 2018-02-12 2020-08-20 Interna Technologies B.V. Anticancer microRNA and lipid formulations thereof
WO2019178479A1 (en) * 2018-03-16 2019-09-19 Sarepta Therapeutics, Inc. Chimeric peptides for antisense delivery
EP3792269A4 (en) * 2018-05-10 2022-06-22 Nippon Shinyaku Co., Ltd. PROCESS FOR PREPARING AN OLIGONUCLEIC ACID COMPOUND
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
EP3918069A1 (en) 2019-01-31 2021-12-08 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
EP3959319A4 (en) 2019-04-25 2023-06-07 Avidity Biosciences, Inc. NUCLEIC ACID COMPOSITIONS AND METHODS FOR MULTI-EXON SKIPPING
JP7581252B2 (ja) 2019-06-06 2024-11-12 アビディティー バイオサイエンシーズ，インク． Ｕｎａアミダイトおよびその使用
US11578090B2 (en) 2019-06-06 2023-02-14 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
WO2020257489A1 (en) 2019-06-19 2020-12-24 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
AU2020411964A1 (en) 2019-12-26 2022-06-16 National Center Of Neurology And Psychiatry Antisense nucleic acid that induces skipping of exon 50
PE20230237A1 (es) 2020-02-28 2023-02-07 Nippon Shinyaku Co Ltd Acidos nucleicos antisentido que inducen la omision del exon 51
AU2021237465A1 (en) 2020-03-19 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
IL296393B1 (en) 2020-03-27 2025-12-01 Avidity Biosciences Inc Compositions and methods of treating muscle dystrophy
AU2021270720A1 (en) 2020-05-11 2022-12-08 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
CN111575409B (zh) * 2020-05-23 2023-04-18 黑龙江八一农垦大学 基于整合素配体识别肽抑制猪流行性腹泻病毒感染的研究方法
WO2022106695A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
EP4332223A4 (en) * 2021-04-28 2025-12-31 Nippon Shinyaku Co Ltd ANTIVIRAL NUCLEIC ACID
US12378267B2 (en) 2021-06-17 2025-08-05 Entrada Therapeutics, Inc. Synthesis of FMOC-protected morpholino monomers and oligomers
AU2022298028A1 (en) 2021-06-23 2023-12-21 National Center Of Neurology And Psychiatry Combination of antisense oligomers
WO2023282346A1 (ja) 2021-07-08 2023-01-12 日本新薬株式会社 析出抑制剤
IL310003A (en) 2021-07-08 2024-03-01 Nippon Shinyaku Co Ltd Nephrotoxicity reducing agent
JPWO2023282344A1 (enExample) 2021-07-08 2023-01-12
US20250011777A1 (en) 2021-09-03 2025-01-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
AU2022358322A1 (en) 2021-09-30 2024-05-16 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
JP2024539223A (ja) 2021-10-22 2024-10-28 サレプタ セラピューティクス， インコーポレイテッド 末梢ミエリンタンパク質２２関連疾患の処置のためのモルフォリノオリゴマー
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2023205451A1 (en) 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
EP4590311A2 (en) 2022-09-21 2025-07-30 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency
IT202200026595A1 (it) 2022-12-22 2024-06-22 Fond Telethon Ets Nuovi inibitori di regolatori epigenetici
TW202444908A (zh) 2023-04-06 2024-11-16 大陸商上海舶望製藥有限公司 ５＇－膦酸酯修飾的核苷類似物及其製備的寡核苷酸
WO2024227040A1 (en) 2023-04-27 2024-10-31 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of chronic kidney disease
WO2025030099A1 (en) 2023-08-02 2025-02-06 Sarepta Therapeutics, Inc. Non-canonical cell-penetrating peptides for antisense oligomer delivery
WO2025085810A2 (en) 2023-10-18 2025-04-24 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of centronuclear myopathies
CN120058705A (zh) * 2025-04-29 2025-05-30 苏州诺维康生物科技有限公司 一种医药中间体PMO-G(N2-iBu)的合成方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5661386A (en) 1985-03-15 1986-10-13 Stirchak, E. Stereoregular polynucleotide-binding polymers
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
DE69033986T2 (de) * 1989-12-20 2003-03-13 Antivirals Inc., Portland Ungeladene, auf Morpholin basierende Polymere mit Chiralen, Phosphor enthaltenden Brücken zwischen den Untereinheiten
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
FI930628A7 (fi) 1990-08-14 1993-03-24 Isis Pharmaceuticals Inc Influenssavirus tyypin A Ann Arbor-kannan H2N2 inhibointi antisense-ol igonukleotideillä
WO1993001286A2 (en) 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5576302A (en) 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
WO1993013226A1 (en) 1991-12-23 1993-07-08 Chiron Corporation Hav probes for use in solution phase sandwich hybridization assays
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6060456A (en) 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
GB9510718D0 (en) 1995-05-26 1995-07-19 Sod Conseils Rech Applic Antisense oligonucleotides
US5955318A (en) 1995-08-14 1999-09-21 Abbott Laboratories Reagents and methods useful for controlling the translation of hepatitis GBV proteins
US6686338B1 (en) 1996-02-23 2004-02-03 The Board Of Regents Of The University Of Nebraska Enzyme inhibitors for metabolic redirection
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
AUPP398498A0 (en) 1998-06-09 1998-07-02 Silverbrook Research Pty Ltd A method of manufacture of an image creation apparatus (ijm44)
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6228579B1 (en) 1997-11-14 2001-05-08 San Diego State University Foundation Method for identifying microbial proliferation genes
AU743695B2 (en) 1998-07-13 2002-01-31 Board Of Regents Of The University Of Nebraska, The Targeted site specific drug delivery compositions and method of use
KR20010102992A (ko) 1999-01-29 2001-11-17 추후보정 표적 ｒｎａ를 검출하는 비-침입적 방법
US7094765B1 (en) 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
US20030095953A1 (en) 1999-11-12 2003-05-22 Myles C. Cabot Methods of reversing drug resistance in cancer cells
US6677153B2 (en) 1999-11-29 2004-01-13 Avi Biopharma, Inc. Antisense antibacterial method and composition
KR20020079768A (ko) 2000-01-04 2002-10-19 에이브이아이 바이오파마 인코포레이티드 안티센스 항박테리아 세포분열 조성물 및 방법
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
DE60143085D1 (de) 2000-05-17 2010-10-28 Univ Nebraska Morpholino antisense oligomere als enzyminhibitoren zur verbesserung der pharmacokinetik eines wirkstoffs
EP3020804A1 (en) 2000-07-06 2016-05-18 Sarepta Therapeutics, Inc. Transforming growth factor beta (tgf- ) blocking agent-treated stem cell composition and method
CN1509292A (zh) * 2001-05-17 2004-06-30 AVI������ҩ��˾ 使用c-myc反义寡聚物治疗癌症的结合的方法
CA2463641C (en) 2001-10-16 2013-07-09 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssrna viral infection
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
US20030207907A1 (en) 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
AU2003267785C1 (en) 2002-09-13 2009-12-24 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US7115374B2 (en) 2002-10-16 2006-10-03 Gen-Probe Incorporated Compositions and methods for detecting West Nile virus
US7615629B2 (en) 2002-12-31 2009-11-10 Sigma-Aldrich Co. Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support
WO2005030800A2 (en) 2003-08-05 2005-04-07 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
EP1713332A4 (en) 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
WO2006085973A2 (en) 2004-07-02 2006-08-17 Avi Biopharma, Inc. Antisense antibacterial method and compound
US8129352B2 (en) * 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
TW200622777A (en) * 2004-12-31 2006-07-01 Inventec Corp Manufacturing-order giving system and method thereof
WO2007030691A2 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
CA2621964A1 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8785407B2 (en) 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection

Similar Documents

Publication Publication Date Title
JP2010505741A5 (enExample)
SI2024499T1 (en) Analogues of the oligonucleotide, with cationic links between subunits
JP2014515762A5 (enExample)
US10106796B2 (en) Compound and method for treating myotonic dystrophy
JP2012506703A5 (enExample)
US20200392498A1 (en) Polynucleotide constructs having bioreversible and non-bioreversible groups
AU2011257980B2 (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
JP2011006428A5 (enExample)
JP2021113232A (ja) ペプチドオリゴヌクレオチドコンジュゲート
JP2022095872A5 (enExample)
JP4974890B2 (ja) ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法
JP2018518201A5 (enExample)
JP2019514426A5 (enExample)
JP2007504830A5 (enExample)
JP2015501817A5 (enExample)
JP2020503049A5 (enExample)
JP2015528002A5 (enExample)
JP2014231516A5 (enExample)
Dragulescu-Andrasi et al. Cell-permeable GPNA with appropriate backbone stereochemistry and spacing binds sequence-specifically to RNA
JP2019512478A5 (enExample)
JP2012503024A5 (enExample)
JP2014520120A5 (enExample)
JP2007530441A5 (enExample)
JP2014518546A5 (enExample)
JP2021506312A (ja) 鋳型指向性の核酸標的化合物